Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468156 | 0.94 | CYP2A6 (0.45) | CYP2A6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3566280 | 0.94 | CYP2A6 (0.45) | CYP2A6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30357699 | 0.87 | LMNA (0.48) | ALDH1A1CA2LMNAHSD17B10TDP1 | |
| SCHEMBL2263563 | 0.87 | LMNA (0.48) | ALDH1A1CA2LMNAHSD17B10TDP1 | |
| SCHEMBL5526773 | 0.83 | CYP2A6 (0.50) | CYP2A6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2263247 | 0.80 | LMNA (0.46) | ALDH1A1CA2LMNAHSD17B10TDP1 | |
| SCHEMBL30615201 | 0.80 | LMNA (0.46) | ALDH1A1CA2LMNAHSD17B10TDP1 | |
| SCHEMBL4625949 | 0.79 | SNCA (0.51) | CYP2A6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3882038 | 0.79 | LMNA (0.64) | CYP2A6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6926484 | 0.79 | CYP2A6 (0.46) | CYP2A6MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| CN-100387576-C | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2008-05-14 | — | — | CN | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7173025-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| US-7109200-B2 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-0880502-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| CN-1193276-A | Use of oxido-squalene cyclase inhibitors for lowering cholesterol in blood | ZENECA LTD (GB) | 1998-09-16 | — | — | CN | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
| WO-1997029104-A1 | AMINOHETEROCYCLIC COMPOUNDS WITH ANTITHROMBOTIC/ANTICOAGULANT EFFECT | ZENECA LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
| WO-1997028129-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | CYP2A6 655/4885MEN1 1291/4885KMT2A 417/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | CYP2A6 736/4885MEN1 1197/4885KMT2A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.